103 related articles for article (PubMed ID: 35945164)
1. Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
Steffanoni S; Calimeri T; Laurenge A; Fox CP; Soussain C; Grommes C; Tisi MC; Boot J; Crosbie N; Visco C; Arcaini L; Chaganti S; Sassone MC; Alencar A; Armiento D; Romano I; Dietrich J; Itchaki G; Bruna R; Fracchiolla NS; Arletti L; Venditti A; Booth S; Musto P; Hoang Xuan K; Batchelor TT; Cwynarski K; Ferreri AJM
Br J Haematol; 2022 Nov; 199(4):507-519. PubMed ID: 35945164
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 infection in patients with primary central nervous system lymphoma.
Laurenge A; Ursu R; Houillier C; Abdi B; Tebano G; Quemeneur C; Choquet S; Di Blasi R; Lozano F; Morales A; Durán-Peña A; Sirven-Villaros L; Mathon B; Mokhtari K; Bielle F; Martin-Duverneuil N; Delattre JY; Marcelin AG; Pourcher V; Alentorn A; Idbaih A; Carpentier AF; Leblond V; Hoang-Xuan K; Touat M
J Neurol; 2021 Sep; 268(9):3072-3080. PubMed ID: 33387015
[TBL] [Abstract][Full Text] [Related]
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
4. Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders?
Murta V; Villarreal A; Ramos AJ
ASN Neuro; 2020; 12():1759091420954960. PubMed ID: 32878468
[TBL] [Abstract][Full Text] [Related]
5. The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients.
Yashavantha Rao HC; Jayabaskaran C
J Med Virol; 2020 Jul; 92(7):786-790. PubMed ID: 32320066
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, China.
Zhang L; Dong L; Ming L; Wei M; Li J; Hu R; Yang J
BMC Pregnancy Childbirth; 2020 Jul; 20(1):394. PubMed ID: 32641013
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
11. Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab-Challenging Recognition and Treatment.
Łyżwa E; Sobiecka M; Lewandowska K; Siemion-Szcześniak I; Barańska I; Klatt M; Langfort R; Szturmowicz M; Tomkowski W
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992402
[TBL] [Abstract][Full Text] [Related]
12. Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies.
Calderón-Parra J; Múñez-Rubio E; Fernández-Cruz A; García-Sánchez MC; Maderuelo-González E; López-Dosil M; Calvo-Salvador M; Baños-Pérez I; Valle-Falcones M; Ramos-Martínez A
Clin Infect Dis; 2022 May; 74(10):1786-1794. PubMed ID: 34383032
[TBL] [Abstract][Full Text] [Related]
13. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
14. Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report.
Nilius-Eliliwi V; Mika T; Baraniskin A; Wünnenberg M; Maslova M; Boy C; Klein-Scory S; Schroers R; Vangala D
Front Oncol; 2021; 11():706431. PubMed ID: 34336692
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
16. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
17. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system.
Zhang Y; Geng X; Tan Y; Li Q; Xu C; Xu J; Hao L; Zeng Z; Luo X; Liu F; Wang H
Biomed Pharmacother; 2020 Jul; 127():110195. PubMed ID: 32361161
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.
Lai CC; Shih TP; Ko WC; Tang HJ; Hsueh PR
Int J Antimicrob Agents; 2020 Mar; 55(3):105924. PubMed ID: 32081636
[TBL] [Abstract][Full Text] [Related]
20. Comment on "Central Nervous System Involvement by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2)".
Chen S; Lu H; Liu Z; Yuan W
J Med Virol; 2020 Sep; 92(9):1399-1400. PubMed ID: 32383264
[No Abstract] [Full Text] [Related]
[Next] [New Search]
